Navignostics is a precision oncology company pioneering the use of spatial single-cell proteomics to transform cancer diagnostics and treatment selection. Founded in 2022 as a spin-off from the University of Zurich’s Bodenmiller Lab, Navignostics combines highly multiplex tumor imaging with advanced data analytics to guide clinicians in identifying the most effective, personalized therapies for each cancer patient.
Swiss Technology Award 2025: Nanotechnology and precision medicine lead the way (startupticker.ch)
Das Finalisten-Feld des Swiss Technology Award 2025 (startupticker.ch)
Key milestones bring startups close to launching vital medical solutions (startupticker.ch)
The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100)
Innosuisse funded 45 Start-up innovation projects (startupticker.ch)
Companies worldwide embrace digitalisation with Swiss startups (startupticker.ch)
Venture Leaders Biotech 2023: Captain’s Blog by Navignostics, Mosanna Therapeutics, Limula, and Tandem Therapeutics (venturelab.swiss)
The Venture Leaders Biotech set sail on the Boston roadshow with immersive expert workshops, uniting entrepreneurs and investors in the US market (venturelab.swiss)
Navignostics: The Venture Leader Biotech on a mission to identify optimal cancer treatments for each patient (venturelab.swiss)
Venture Leaders Biotech kick off their Boston roadshow at Swiss Biotech Day (venturelab.swiss)
Ten biotech startups head to Boston (startupticker.ch)
Swiss National Startup Team 2023: 10 biotech innovators are headed to Boston (venturelab.swiss)
Navignostics raises CHF 7.5M to advance precision cancer medicine (startupticker.ch)
UZH Life Science Fund invests in Navignostics (startupticker.ch)
Stage 2 ISO 13485 successful
New and improved website giving a face to our wonderful team in our Horgen labs and offices
Expansion of clinical and industry collaborations to US
Move to Swiss company premises in Horgen